Ismail-Khan R,Bui MM.A review of triple-negative breast cancer[J].Cancer Control,2010,17(3):173-176.
[2]
Ruijter TC,Veeck J,Hoon JP,et al.Characteristics of triple-negative breast cancer[J].J Cancer Res Clin,2011,137(2):183-192.
[3]
Zuber J,Shi J,Wang E,et al.RNAi screen identifies BRD4as a therapeutic target in acute myeloid leukaemia[J].Nature,2011,478:524-528.
[4]
Dawson MA,Prinjha RK,Dittmann A,et al.Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemia[J].Nature,2011,478:529-533.
[5]
Delmore JE,Issa GC,Lemieux ME,et al.BET bromodomain inhibition as a therapeutic strategy to target c-Myc[J].Cell,2011,146:904-917.
[6]
Lockwood WW,Zejnullahu K,Bradner JE,et al.Sensitivity of huma lung adenocarcinoma cell lines to targeted inhibition of BET epigenetic signaling proteins[J].Proc Natl Acad Sci USA,2012,109:19 408-19 413.
[7]
Yang Z,He N,Zhou Q.BRD4recruits P-TEFb to chromosomes at late mitosis to promote G1gene expression and cell cycle progression[J].Mol Cell Bio,2008,l28(3):967-976.
[8]
Dent R,Hanna WH,Trudeau M,et al.Pattern of metastatic spread in triple-negative breast cancer[J].Breast Cancer Res Treat,2009,115:423-428.
[9]
Cheng Z,Gong Y,Ma Y,et al.Inhibition of BET Bromodomain Targets Genetically Diverse Glioblastoma[J].Clin Cancer Res,2013,19:1 748-1 759.
[10]
Perou CM,Sorlie T,Eisen MB,et al.Molecular portraits of human breast tumors[J].Nature,2000,406(6 797):747-752.
[11]
Lin NU,Vanderplas A,Hughes ME,et al.Clinicopathological features and sites of recurrence according to breast cancer subtype in the National Comprehensive Cancer Network(NCCN)[J].J Clin Oncol,2009,27(15):543.
[12]
Belkina AC,Denis GV.BET domain co-regulators in obesity,inflammation and cancer[J].Nat Rev Cancer,2012,12:465-477.
